Aclaris Therapeutics, Inc. (ACRS): Cost of Revenue
$2.09M
Year ended 2025-12-31
$1.68M
Trailing 12 months to 2026-06-30
-19.6%
3-year compound annual growth
-16.4%
5-year compound annual growth
| Period ended | Cost of Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $2.09M | -25.1% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $2.79M | -18.4% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $3.42M | -14.9% | 2025-02-27, From 2023-01-01 |
| 2022-12-31 | $4.02M | -14.6% | 2024-02-27, From 2022-01-01 |
| 2021-12-31 | $4.71M | -8.2% | 2024-02-27, From 2021-01-01 |
| 2020-12-31 | $5.13M | +26.6% | 2023-02-23, From 2020-01-01 |
| 2019-12-31 | $4.05M | -6.3% | 2022-02-24, From 2019-01-01 |
| 2018-12-31 | $4.33M | +258.7% | 2021-02-25, From 2018-01-01 |
| 2017-12-31 | $1.21M | n/a | 2020-02-25, From 2017-01-01 |
Cost of Revenue at similar companies
| Company | Year ended | Cost of Revenue | Change YoY |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | 2025-12-31 | $2.09M | -25.1% |
| Whitehawk Therapeutics, Inc. (WHWK) | 2025-12-31 | $760.0K | -74.9% |
| International Stem Cell Corp (ISCO) | 2025-12-31 | $4.03M | +7.1% |
| Jaguar Health, Inc. (JAGX) | 2025-12-31 | $3.77M | +93.0% |
| Emmaus Life Sciences, Inc. (EMMA) | 2025-12-31 | $857.0K | -28.6% |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | 2025-12-31 | $6.64M | -14.5% |
| CV Sciences, Inc. (CVSI) | 2025-12-31 | $7.04M | -17.6% |
| Pyxis Oncology, Inc. (PYXS) | 2025-12-31 | $2.39M | +402.7% |
| ProPhase Labs, Inc. (PRPH) | 2025-12-31 | $2.96M | -57.2% |
Compare ACRS, WHWK, ISCO, JAGX side by side · Screen every company in Pharmaceutical Preparations ↗